Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010

2020 ◽  
Vol 138 ◽  
pp. 113-121
Author(s):  
Shiliang Liu ◽  
Jing Wen ◽  
Hong Yang ◽  
Qiaoqiao Li ◽  
Yuping Chen ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Neoadjuvant Chemoradiotherapy ◽  
Phase Iii ◽  
Oesophageal Squamous Cell Carcinoma ◽  
Phase Iii Trial ◽  
Multicenter Phase ◽  
Recurrence Patterns

scholarly journals LUX-Lung 8 phase III trial: Analysis of long-term response to second-line afatinib in patients with advanced squamous cell carcinoma (SCC) of the lung

2017 ◽  
Vol 28 ◽  
pp. ii37 ◽  
Author(s):  
J.C.-H. Yang ◽  
G. Goss ◽  
E. Felip ◽  
S. Lu ◽  
A. Ardizzoni ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Phase Iii ◽  
Advanced Squamous Cell Carcinoma ◽  
Second Line ◽  
Phase Iii Trial ◽  
Trial Analysis ◽  
Term Response

Double blind multicenter phase III GORTEC trial evaluating the efficacy of oral immune modulating formulae therapy during adjuvant radiochemotherapy in head and neck squamous cell carcinoma (HNSCC).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 6066-6066
Author(s):  
Pierre Boisselier ◽  
Pierre Graff-Cailleaud ◽  
Christian Sire ◽  
Olivier Gallocher ◽  
Sandrine Lavau-Denes ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma ◽  
Phase Iii ◽  
Double Blind ◽  
Adjuvant Radiochemotherapy ◽  
Multicenter Phase

Randomized Trial of Adjuvant 13-cis-Retinoic Acid and Interferon Alfa for Patients With Aggressive Skin Squamous Cell Carcinoma

2007 ◽  
Vol 25 (15) ◽  
pp. 1974-1978 ◽  
Author(s):  
Abenaa M. Brewster ◽  
J. Jack Lee ◽  
Gary L. Clayman ◽  
John L. Clifford ◽  
Mary Jo T. Necesito Reyes ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Retinoic Acid ◽  
Adjuvant Therapy ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Tumor Recurrence ◽  
Interferon Alfa ◽  
Phase Iii ◽  
Phase Iii Trial ◽  
Skin Squamous Cell Carcinoma

Purpose To conduct a phase III trial of adjuvant 13-cis-retinoic acid (13cRA) plus interferon alfa (IFN-α) for preventing tumor recurrence and second primary tumors (SPTs) of skin squamous cell carcinoma (SCC) among patients with aggressive skin SCC. Patients and Methods Sixty-six patients with aggressive skin SCC were randomly assigned to receive either 6 months of combined 13cRA (1 mg/kg/d orally) and IFN-α (3 × 106 U subcutaneously three times per week) or no adjuvant therapy (control group) after SCC surgery and/or radiation. Results At 21.5 months median follow-up, treatment did not improve the time to tumor recurrence and SPT versus control (hazard ratio [HR], 1.13; 95% CI, 0.53 to 2.41), time to tumor recurrence (HR, 1.08; 95% CI, 0.43 to 2.72), or time to SPT (HR, 0.89; 95% CI, 0.27 to 2.93). Adjuvant 13cRA and IFN-α was moderately tolerable; 29% of patients in the treatment arm required dose reductions for grade 3 or 4 toxicities. Conclusion Results of this phase III trial do not support 13cRA plus IFN-α for adjuvant therapy of aggressive skin SCC. With high rates of tumor recurrence and SPTs, patients with aggressive skin SCC continue to have an unmet medical need, with devastating mortality, morbidity, and financial consequences. Promising agents with preclinical and early clinical results relevant to aggressive skin SCC deserve a high priority for future clinical drug development.

Sign in / Sign up

Export Citation Format

Share Document